Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 170787-99-2 | 產品號碼: E1356
Efaproxiral Sodium
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
產品規格
| Appearance | White to Almost white powder to lump |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 %(calcd.on anh.substance) |
| Melting point | 240.0 to 244.0 °C |
| Water | max. 13.0 % |
| NMR | confirm to structure |
性質
GHS
相關法規
運輸資料
| HS編碼* | 2924.29-000 |
Application
Efaproxiral Sodium: Developed as an Allosteric Modifier of Hemoglobin and a Radiation Sensitizer
Efaproxiral sodium (RSR 13 sodium), an analogue of the antilipemic agent bezafibrate [B3346], was developed as an allosteric modifier of hemoglobin1,2) and a radiation sensitizer.3) In the 2000s, efaproxiral sodium was tested in a clinical trial to increase the efficacy of certain chemotherapy agents which have reduced efficacy against hypoxic tumors, and can thus be made more effective by increased offloading of oxygen from hemoglobin-bound oxygen into the tumor tissues.4) But the clinical trial was dropped out in Phase III trials. In 2009, Efaproxiral was added to the World Anti-Doping Agency (WADA) list of Prohibited Substances as an artificially enhancer of the uptake, transport or delivery of oxygen.5) (The product is for research purpose only.)
References
- 1) Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents
- 2) Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats
- 3) Radiation sensitization with redox modulators: a promising approach (a review)
- 4) Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo
- 5) Preventive doping control screening analysis of prohibited substances in human urine using rapid-resolution liquid chromatography/high-resolution time-of-flight mass spectrometry
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。